, and the NATO tamoxifen study (NATO, 1983). These trials were set up in 1965 and 1977 respectively to address questions relating to 'soft option' adjuvant systemic therapy, and both subsequently described an improvement in disease-free and overall survival (NATO, 1983; Nissen-Meyer et al., 1978) . The Scandinavian trial incorporated a 6 day perioperative course of cyclophosphamide and with a follow-up of more than 15 years has shown an increase in both disease-free and overall survival for patients given this low toxicity regimen; very few other trials have investigated perioperative chemotherapy (Houghton et al., 1987). Primary therapy was either total mastectomy with axillary
Although one woman in twelve will develop breast cancer in her lifetime very few of these will be entered into a prospective randomized clinical trial (Tate et al., 1979) , despite there still being much uncertainty about the best treatment for the disease. In order to detect small but nevertheless clinically worthwhile differences large trials are needed. Many patients must therefore be recruited over a relatively short time period. This requires the cooperation of many clinicians not only in large teaching hospitals with Specialist Units but also in the District General Hospital where the number of eligible patients may be relatively small but where the majority of patients in this country are nevertheless treated. For this reason the trial protocols must address pertinent questions and be easy to implement in busy surgical departments which do not have the advantages of Specialist Oncology Services.
The CRC Adjuvant Breast Trial which was launched in 1981 was designed to fulfill these criteria. The aim of this study was to replicate the cyclophosphamide trial of the Scandinavian Adjuvant Chemotherapy Study Group (NissenMeyer et al., 1982) , and the NATO tamoxifen study (NATO, 1983) . These trials were set up in 1965 and 1977 respectively to address questions relating to 'soft option' adjuvant systemic therapy, and both subsequently described an improvement in disease-free and overall survival (NATO, 1983; Nissen-Meyer et al., 1978) . The Scandinavian trial incorporated a 6 day perioperative course of cyclophosphamide and with a follow-up of more than 15 years has shown an increase in both disease-free and overall survival for patients given this low toxicity regimen; very few other trials have investigated perioperative chemotherapy (Houghton et al., 1987 Figure 1 ). The beneficial effect is evident in all tamoxifen treated subgroups when stratified by menstrual or nodal status (Table II) , it is from these strata that the overall adjusted x2 has been calculated.
The incidence of new contralateral breast carcinomas was significantly reduced in the tamoxifen group (tam = 7, control= 18, logrank X2=5.39, P=0.02).
Despite an advantage being seen in favour of the tamoxifen group with regard to time to first event, this has not been translated into a survival benefit, although there is a trend in the same direction (tam = 166, control = 194, logrank X2= 1.63, P=0.20; deaths from all causes).
Br. J. Cancer (I 988), 57, [604] [605] [606] [607] Figure 2 ). When stratified by menstrual and nodal status this beneficial effect is demonstrated in all but the premenopausal node positive subgroup (Table III) . The overall adjusted x2 has been calculated from the strata.
Currently no significant effect of cyclophosphamide on overall survival is seen. A total of 386 deaths have been recorded (cyclo=185, control=201, X2=1.49, P=0.22).
Cox's regression analysis and treatment interactions
A Cox regression analysis was performed on first event rates; nodal status, tumour size and tamoxifen therapy were found to be important predictors of time to first event. There was also a suggestion that cyclophosphamide therapy may be of importance. No significant interactions between any of these factors were found. The lack of interaction between the two treatments is confirmed upon subgroup analysis. A four way (2 x 2) randomization such as this lends itself to six different comparisons (Table IV) . When examining all of these possibilities it is necessary to make a correction for multiple comparisons, e.g. a Bonferoni statistic which requires a Time (years) Figure 3 Four group analysis -First event.
x2> 7 for significance, rather than the usual value of x 2>3.84. Figure 3 illustrates the event-free survival in each of the four groups of patients in life-table format.
Analysis of survival time by Cox's multiple regression analysis demonstrated that nodal status was important, but no other variables were found to be of predictive value.
Discussion
The results from the CRC Adjuvant Breast Trial are very similar to those obtained in the two earlier trials at a similar point of follow-up.
Analysis of the tamoxifen main effect has shown an improvement in event-free survival for both pre-and postmenopausal patients receiving tamoxifen. The latter is consistent with many other tamoxifen trials -the majority of which only recruited postmenopausal patients (NATO, 1985; Wilson et al., 1985; Palshof, 1981; Ribeiro & Palmer, 1983; Wallgren et al., 1983; Rose et al., 1983; Pritchard et al., 1984; Scottish Cancer Trials Office, 1987) . However the CRC Adjuvant Breast Trial was also open to premenopausal patients, irrespective of nodal status and there was a significant benefit in this subgroup for those who received tamoxifen, similar to that described by the Scottish trial. Multiple regression analysis also failed to demonstrate any interactions, supporting the view that tamoxifen was having similar effects in all subgroups. The recent World Overview of tamoxifen trials (Anonymous, 1984; BCTCS/UICC/WHO, 1985) showed no benefit of tamoxifen in the premenopausal group, but this may be due to the relatively low numbers of patients and short follow-up interval. In addition the majority also received systemic adjuvant chemotherapy which may have pre-empted the tamoxifen effect via a chemical castration.
As yet a survival advantage for adjuvant tamoxifen has not emerged within this trial. There are three possible explanations for this. Firstly, that the estimate of survival advantage in trials previously reported was exaggerated as a result of random bias. Secondly, that insufficient deaths have occurred to detect a 20-30% reduction in the five year m'ortality rates or, thirdly, that the follow-up has been insufficient to allow that group of patients with an excess of distant metastases in the control group to experience the lethality of those events. Referring back to the statistical overview of adjuvant tamoxifen trials, the second and third explanations are the most likely.
Results obtained in the cyclophosphamide comparison are also showing a significant benefit in favour of the treated group. Despite a similar benefit first reported by the SACSG, this regimen has not been incorporated into general clinical practice. The results reported now support those previously obtained (Nissen-Meyer et al., 1986 , and although the benefit may be small it could be clinically worthwhile. However, with the data from the overview showing a significant benefit for patients under 50 years given prolonged adjuvant chemotherapy, the exact place of perioperative cyclophosphamide therapy in the treatment of early breast cancer has still to be defined, and long-term follow-up is required. The regimen is much less toxic than cyclical polychemotherapy and it may therefore be of importance for patients either not fit for or not willing to undergo the more complex treatment schedules, or for those treated in Units without access to the expertise of a Medical Oncologist.
Inspection of the life table for event free survival within the four therapeutic sub-groups of the trial (Figure 3) gives an impression of a rank order of benefit. Great caution has to be recommended not to over-interpret what appears to be a tidy and intuitively satisfying result. As already described above, the Cox's Regression Analysis for sub-group comparisons fails to show any significant treatment interactions. However, with nearly 500 patients in each arm there is a reasonable chance that, in the long term, we might be able to answer the question as to whether the benefit of cyclophosphamide and tamoxifen treatment are additive, synergistic or antagonistic when given together.
In conclusion, at a median follow-up of approximately three years the CRC Adjuvant Trial has demonstrated that a six day course of perioperative cyclophosphamide or two years of tamoxifen, significantly improves the event-free survival. These results closely mirror those obtained by the Scandinavian and NATO groups.
Perhaps the most important new observations within this study are the suggestion that adjuvant tamoxifen can prevent the development of a new contralateral primary and that its benefits are equally felt amongst the premenopausal as well as the postmenopausal patients irrespective of nodal status. So far there is no evidence that the addition of longterm tamoxifen to perioperative cyclophosphamide produces a greater benefit than either agent given alone.
